News
Tech Month | Wanbangde Pharmaceutical Group Steadily Advances Multiple Specialized Training Sessions and Expert Exchange Activities
Date:
03 Jun,2024
This year, from May 25 to June 1, the 2024 National Science and Technology Week was jointly hosted by the Ministry of Science and Technology, the Publicity Department of the Central Committee, and the China Association for Science and Technology. Wanbangde Pharmaceutical Group kicked off its first-ever "Science and Technology Month" event on May 11. Theme: "Bringing Together Great Minds for Growth, Driving Innovation to Shape the Future" As part of the "Science and Technology Month" initiative, the company has organized a variety of science and technology training sessions, along with interactive workshops featuring close, on-site discussions and exchanges with leading experts in the field.
Professional training on domestic and international drug registration and eCTD, empowering companies in pharmaceutical submissions
To accelerate the implementation of the electronic Common Technical Document (eCTD) system for pharmaceuticals, the company held a training session on drug registration and eCTD on May 11 in the conference room on the 10th floor of the R&D Building. The training was conducted both in person and online, with all members of the R&D Center attending.
Experts delivered training divided into two key parts: an introduction to the eCTD regulatory framework and how companies can prepare for it, as well as a detailed analysis of the eCTD submission process—including hands-on practice and validation. This helped participants stay up-to-date on eCTD submission principles and submission workflows, ultimately enhancing the quality of their regulatory documents. Attendees also actively shared their questions and insights throughout the session.
Going forward, the company will continue to organize training sessions focused on enhancing the quality of registration submissions and building the eCTD system, fostering consensus, accelerating adoption, and collectively driving improvements in the quality of our pharmaceutical submissions. This training session also lays a solid foundation for the international registration of the company’s products.
Active pharmaceutical ingredient process development and quality research training—empowering companies to enhance quality and boost efficiency.
To enhance the quality and efficiency of the company’s API process development, standardize and optimize the API manufacturing workflows, and ultimately accelerate R&D progress and bring products to market more swiftly, the company invited Dr. Bao Liu, Senior Director of the Process Department at Shanghai Medicilon, and Dr. Jian Wang, Chief Scientist (Analytical) at Zhejiang Heze Pharmaceutical Technology Co., Ltd., to deliver lectures on API process development and quality research on May 19.
Dr. Liu Bao presented insights from three perspectives: process design principles and methods, process optimization and improvement, and process evaluation and comparison. Meanwhile, Dr. Wang Jian shared expertise in three key areas: quality standards and regulations, impurity research strategies, and critical considerations for stability studies of both active pharmaceutical ingredients and finished dosage forms. Both professors emphasized that, while ensuring product quality remains controllable, safe, and effective, it is equally important to focus on the practicality of quality standards.
This training was incredibly beneficial, guiding participants to align their research approaches with the unique characteristics of the drugs being developed and the inherent principles of drug production. It emphasized the importance of clearly defining research strategies, standardizing quality assessments, establishing robust quality criteria, and systematically revising and refining these standards—ultimately helping to elevate the overall quality of pharmaceutical standards.
Oral solid dosage form training helps companies accelerate product launches.
To enhance the quality and efficiency of the company’s pharmaceutical research on oral solid dosage forms, standardize and optimize the R&D process for solid formulations, and ultimately accelerate development timelines to bring products to market more quickly, the company invited renowned drug review expert Professor Zheng Guogang to deliver an on-site lecture on May 25. Staff from the R&D (Technical) Center, QA teams, and technical personnel from various production workshops actively participated in the training session.
The training focused primarily on pharmaceutical research related to oral solid dosage forms. Instructor Zheng provided a detailed overview of various aspects, including dosage forms and product composition, product development, manufacturing processes, excipient control, formulation quality assurance, reference standards, packaging systems, and stability studies. The presentation materials were enriched with real-world case studies, offering in-depth analysis that was both engaging and easy to understand, leaving participants deeply educated and inspired.
This "Tech Month" special training featured rich content with a clear and compelling theme. Through the session, R&D personnel not only strengthened their awareness of legal regulations, quality standards, and accountability but also gained a deeper understanding of the critical importance of balancing quality and efficiency in the execution of research and development projects. We left inspired—reflecting on what we learned and already reaping tangible benefits. Moving forward, we’re committed to applying these insights effectively in our future research endeavors, further empowering the company as a technology-driven and innovation-focused enterprise.
Related Recommendations